-
Posted by
Two Blokes May 15 -
Filed in
Stock
-
4 views
WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), received confirmation that the updated formulation of the Ameluz\u00ae nanoemulsion gel without propylene glycol received patent approval through to December 2043. The formulation was earlier accepted for use in Ameluz\u00ae by the US Food and Drug Administration (FDA) and is in use since 2024. In addition to this long-lasting protection of Ameluz\u00ae against generic competition, Biofrontera today announced the successful enrollment of the final patient in its Phase 2b clinical trial evaluating Ameluz\u00ae (aminolevulinic acid hydrochloride) for the treatment of moderate to severe acne vulgaris.
